Literature DB >> 10448301

FHIT gene abnormalities in both benign and malignant thyroid tumours.

M Zou1, Y Shi, N R Farid, S T al-Sedairy, M C Paterson.   

Abstract

FHIT, a candidate tumour suppressor gene, has recently been identified at chromosomal region 3p14.2, and deletions of the gene have been reported in many types of human cancers. Loss of heterozygosity (LOH) at this region has also been found frequently in follicular thyroid carcinoma (FTC). To investigate the potential role of FHIT in thyroid tumorigenesis, we examined 57 thyroid tumour specimens (eight benign adenomas, 40 papillary, four follicular and five anaplastic carcinomas), and two thyroid carcinoma cell lines (NPA, SW579) for genetic alterations by using reverse transcription-polymerase chain reaction (RT-PCR), PCR product sequencing, single-strand conformation polymorphism (SSCP) and Southern blot analysis. Two cervical carcinoma cell lines (C-33A, HeLa) were included as positive controls. We detected truncated FHIT transcripts in three of eight (38%) benign adenomas, nine of 40 (23%) papillary, and two of five (40%) anaplastic carcinomas, and in three cell lines (SW579, C-33A, HeLa). Most of the truncated transcripts lacked exons 4 or 5 to 7 or 8 of the gene and were presumably non-functional as the translation start site is located in exon 5. SSCP analysis of the coding exons failed to detect any point mutations among the samples without abnormal FHIT transcripts. Southern blot analysis demonstrated either loss or reduced intensity of major Bam HI restriction fragments in the three cell lines found to have abnormal FHIT transcripts, indicating, respectively, either intragenic homozygous or heterozygous deletions of the FHIT gene. Intragenic homozygous deletions were also found in two papillary thyroid carcinoma specimens: one was missing a 13 kb Bam HI fragment which contains exon 4, the other had deletions of 15.5, 13 and 4.2 kb fragments which contain exons 2 and 9, 4, and 5, respectively. The absence of a defective FHIT gene in FTC indicates that an additional tumour suppressor gene may reside in this region and be involved in the development of FTC. Given that defective FHIT genes were found in both benign and malignant thyroid tumours, the inactivation of this putative tumour suppressor gene is likely to be an early event in the pathogenesis of some forms of thyroid neoplasms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448301     DOI: 10.1016/s0959-8049(98)00370-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma.

Authors:  De-Tao Yin; Lin Wang; Jianrui Sun; Fengyan Yin; Qingtao Yan; Rulong Shen; Gang He; Jian-Xin Gao
Journal:  Int J Clin Exp Pathol       Date:  2010-05-25

2.  Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9.

Authors:  Y Shi; M Zou; N R Farid; M C Paterson
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

3.  Analysis of the tumour suppressor genes, FHIT and WT-1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE, MAGE-1, and MAGE-3, in benign and malignant neoplasms of the salivary glands.

Authors:  H Nagel; R Laskawi; H Eiffert; T Schlott
Journal:  Mol Pathol       Date:  2003-08

4.  Association between decreased WWOX protein expression and thyroid cancer development.

Authors:  Eduardo P Dias; Flavio J Pimenta; Marta S Sarquis; Marco A Dias Filho; C M Aldaz; Julienne B Fujii; Ricardo S Gomez; Luiz De Marco
Journal:  Thyroid       Date:  2007-11       Impact factor: 6.568

5.  S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma.

Authors:  M Zou; R S Al-Baradie; H Al-Hindi; N R Farid; Y Shi
Journal:  Br J Cancer       Date:  2005-11-28       Impact factor: 7.640

6.  Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer.

Authors:  Ho-Young Son; Yul Hwangbo; Seong-Keun Yoo; Sun-Wha Im; San Duk Yang; Soo-Jung Kwak; Min Seon Park; Soo Heon Kwak; Sun Wook Cho; Jun Sun Ryu; Jeongseon Kim; Yuh-Seog Jung; Tae Hyun Kim; Su-Jin Kim; Kyu Eun Lee; Do Joon Park; Nam Han Cho; Joohon Sung; Jeong-Sun Seo; Eun Kyung Lee; Young Joo Park; Jong-Il Kim
Journal:  Nat Commun       Date:  2017-07-13       Impact factor: 14.919

Review 7.  Genetic Polymorphism Predisposing to Differentiated Thyroid Cancer: A Review of Major Findings of the Genome-Wide Association Studies.

Authors:  Vladimir A Saenko; Tatiana I Rogounovitch
Journal:  Endocrinol Metab (Seoul)       Date:  2018-06

Review 8.  Artificial Intelligence for Personalized Medicine in Thyroid Cancer: Current Status and Future Perspectives.

Authors:  Ling-Rui Li; Bo Du; Han-Qing Liu; Chuang Chen
Journal:  Front Oncol       Date:  2021-02-09       Impact factor: 6.244

9.  Loss of Heterozygosities in Five Tumor Suppressor Genes (FHIT Gene, p16, pRb, E-Cadherin and p53) in Thyroid Tumors.

Authors:  Jin Hwan Kim; Kyu Young Choi; Dong Jin Lee; Young-Soo Rho; Sung-Jin Jo
Journal:  Clin Exp Otorhinolaryngol       Date:  2014-02-05       Impact factor: 3.372

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.